☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Neurocrine Biosciences
Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD
April 24, 2024
Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder
April 4, 2024
Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenita...
October 6, 2023
Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults
September 13, 2023
PharmaShots Weekly Snapshots (August 21 – 25, 2023)
August 25, 2023
Neurocrine Biosciences’ Ingrezza (valbenazine) Capsules Receives the US FDA’s Approval for the Treatment of Chorea Associated with...
August 21, 2023
Load more...
Back to Home